Information

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer. If, after doing this, organisations still wish to consider the use of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer, they should follow the advice set out in 'Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance' which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the website.

  • National Institute for Health and Care Excellence (NICE)